Monta Biosciences

MonTa Biosciences is a clinical stage biotech company located in the DTU science park in Kgs. Lyngby, Copenhagen. Our lead candidate MBS8 is a novel TLR7 agonist formulated in micelles, which show greater therapeutic activity and better safety profiles compared to non-formulated TLR7 agonists. We are currently running a phase I clinical study in solid tumor cancer patients at sites in Denmark, Belgium and Spain and have dosed more than 20 patients. MBS8 has the unique selling points-MBS8 can turn “Cold” tumors into “Hot” tumors -Strong anti-tumor activity in a broad range of tumor models -Unique MoA based on Neutrophil activation and tumor cell killing -Can be administered intravenously -Show synergy with PD-1/PD-L1 checkpoint inhibitors Get in touch for more info